Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesDermatologyAetna TBP Dermoscopy Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentAetnaPolicy 0188

    Total Body Photography, Dermoscopy and Other Selected Noninvasive Dermatologic Tests

    Customize your policy alerts

    Sign up for Aetna Policy 0188 alerts

    Get alerted when Policy 0188 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs medical necessity and coverage determinations for total body photography (TBP), dermoscopy, and selected noninvasive dermatologic tests for Aetna members, including which uses are considered medically necessary versus experimental/investigational or unproven.

    Policy Summary
    PayerAetna
    PolicyTotal Body Photography, Dermoscopy and Other Selected Noninvasive Dermatologic Tests
    Policy CodePolicy 0188
    Change TypeNo material clinical or coverage changes
    Effective DateDec 1, 1997
    Last ReviewFeb 11, 2027
    Next Review DateFeb 11, 2027
    Key ActionWhen billing CPT 96904 for whole-body integumentary photography, document that the member meets selection criteria (e.g., personal or family history of melanoma or dysplastic nevi) and the intended monitoring interval.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12/01/1997Policy effective
    02/11/2027Next review
    96904Covered CPT (if criteria met)
    24 months

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Typical repeat interval
    >170References cited

    Coverage Criteria

    Medically necessary indications

    Covered when ALL of the following selection criteria are met:

    Eligibility for TBP and dermoscopy: Member has a personal history or close family history of ANY of the following: atypical nevi, dysplastic nevi, melanoma, or non-melanoma skin cancers.

    Repeat studies are not typically required more frequently than every 24 months.

    Experimental, investigational, or unproven

    The following interventions are considered experimental, investigational, or unproven because effectiveness has not been established:

    Unproven technologies (partial list): AdvanceAD-Tx (Castle Biosciences) for atopic dermatitis; AURA (Vita Imaging); Computerized TBP systems (e.g., MelaFind, MoleMapCD, MoleMate); Dermoscopy for vulvar intraepithelial neoplasia; Dermoscopy for delineation of basal cell carcinoma for Mohs micrographic surgery; Dermoscopy for evaluation of non-parasitic skin infections; Hand-held fluorescent molecular imaging (e.g., Orlucent); Skin-surface mRNA adhesive patch (e.g., Mind.Px); TBP and dermoscopy for indications other than the listed medically necessary conditions; Confocal scanning laser microscopy; DermTech Nevome; Electrical impedance devices; High-resolution (high-frequency) ultrasonography; Multi-photon laser scanning microscopy; Multi-spectral image analysis; Non-invasive gene expression patch biopsy (e.g., DermTech PLA); Optical coherence tomography; Reflectance confocal microscopy (RCM); Spectroscopy (electrical/optical); Teledermatology/teledermoscopy; Visual image analysis.

    List is not all-inclusive; technologies above are identified in the policy as experimental, investigational, or unproven for the specified indications.

    Evidence summary — CAD and EIS

    Summary of evidence-based findings and limitations from systematic reviews and primary studies for CAD systems and electrical impedance spectroscopy (EIS):

    CAD systems (Derm-CAD / MSI-CAD): In highly selected populations CAD systems demonstrate high sensitivity but variable and often low specificity. Pooled estimates: Derm-CAD sensitivity ~90.1% (95% CI 84.0–94.0%), specificity ~74.3% (95% CI 63.6–82.7%); MSI-CAD sensitivity ~92.9% (95% CI 83.7–97.1%), specificity ~43.6% (95% CI 24.8–64.5%).

    Included studies were heterogeneous, incompletely reported, and at unclear to high risk of bias, limiting generalizability to routine practice.

    EIS diagnostic performance: Pivotal and subsequent studies report very high sensitivity for melanoma detection (reported up to ~99.4% for one algorithm) but low overall specificity (around 23–25% in some datasets). Survey/pilot studies suggest adding EIS to morphologic assessment can increase sensitivity and change biopsy decisions in a substantial proportion of cases (e.g., ~24% of decisions).

    Many studies used selected lesions, image-based reader designs, or had limitations that reduce applicability to in‑vivo clinical practice; further prospective, real-world studies are needed.

    Adjunctive test utility and limitations

    Adjunctive tests can influence management in specific scenarios but have important limitations and recommended integrations with clinical assessment:

    EIS as an adjunct: EIS may complement dermoscopy and increase sensitivity of biopsy decisions, particularly among clinicians less experienced in dermoscopy; EIS score interpretation (for example, scores <4 suggesting low malignancy risk in some contexts, or protocol thresholds such as >=7 prompting excision) must be integrated with clinical and dermoscopic findings.EIS score thresholds vary by study (e.g., <4, >=7)

    Many supporting studies used image-based designs; in‑vivo impact on outcomes remains limited.

    When to consider additional adjuncts: Consider RCM or other high-sensitivity adjuncts for lesions that are equivocal on clinical and dermoscopic examination or in high-risk patients; if adjunctive testing is discordant with clinical concern (eg, low EIS but lesion change on follow-up), short-term monitoring or excision should be considered.none

    Adjunctive testing should not replace in‑clinic examination and clinical judgment.

    Evidence summaries

    Real-world performance characteristics and study findings that inform coverage considerations:

    HFUS evidence: Targeted high-resolution ultrasound detected sentinel lymph node metastatic deposits down to approximately 4.5 mm but missed smaller deposits; overall sensitivity for detecting SLN metastases is low (~24.3%), so HFUS cannot substitute for SLN biopsy but may assist pre-operative assessment and follow-up.sensitivity ~24.3%; detectable deposit approx. >=4.5 mm

    Based on targeted US studies of SLNs.

    PLA (DermTech Pigmented Lesion Assay) real-world findings: PLA studies and registries reported sensitivity approximately 91%–95%, specificity 69%–91% across cohorts, and negative predictive value >99% in intended-use populations; registries demonstrated that PLA(+) lesions were commonly biopsied and PLA(-) lesions were predominantly surveilled, reducing unnecessary biopsies in practice.NPV >99% reported

    Longitudinal follow-up cohorts reported very low rates of subsequent melanoma among PLA(-) lesions during follow-up intervals studied.

    Evidence summaries relevant to coverage

    Evidence summaries relevant to coverage decisions for Mind.Px and RCM (major findings and limitations):

    Mind.Px (dermal biomarker patch): Mind.Px uses an NGS-based dermal biomarker patch and machine-learning algorithms evaluating >7,000 biomarkers; initial analytic and clinical validation (STAMP) and a randomized MATCH study demonstrated increased concordance of prescribing with test recommendations and improved short-term PASI75 outcomes when care was concordant with Mind.Px recommendations.PASI75 at 12 weeks reported; follow-up duration typically 12 weeks

    Limitations include short-term follow-up, incomplete outcome data for some participants, and need for independent external validation; no published net health benefit outcome studies in routine clinical practice to date.

    RCM (reflectance confocal microscopy): Systematic reviews and meta-analyses report that RCM can have higher diagnostic accuracy than dermoscopy in lesions suspicious or equivocal for melanoma (eg, Pellacani score threshold >=3 with sensitivity ~92%); however, many primary studies have high or unclear risk of bias and applicability concerns, and evidence for RCM in diagnosing BCC or cSCC is insufficient.Pellacani RCM score >=3 sensitivity ~92%

    Prospective, real-world comparative studies are needed; RCM has limitations including depth penetration and heterogeneous terminology for non-melanocytic lesions.

    TBP (total body photography) and dermoscopy are considered medically necessary only for the specific high‑risk indications listed in this policy (for example, personal or close family history of melanoma, atypical or dysplastic nevi, or non‑melanoma skin cancer). Use of TBP or dermoscopy for indications outside those listed is identified in the policy as experimental, investigational, or unproven because effectiveness has not been established; examples of unproven technologies include computerized TBP systems (e.g., MelaFind, MoleMapCD, MoleMate), AURA, DermTech Nevome, and multiple other listed modalities. Repeat TBP/dermoscopy is generally not required more frequently than every 24 months unless clinically justified.

    Systematic reviews of computer‑aided diagnosis (CAD) and spectroscopy‑based systems report high sensitivity for melanoma detection in highly selected study populations but substantial and variable low specificity, and the primary studies are heterogeneous and at unclear or high risk of bias. Review authors concluded that the existing evidence is insufficient to demonstrate that CAD outputs reliably translate into different clinical decision‑making or improved health outcomes in routine practice.

    DermTech Nevome is an adhesive‑patch DNA mutation analysis intended to complement PLA by assaying mutations (e.g., BRAF, NRAS, TERT promoter) from noninvasively collected tissue. According to the company, Nevome is currently ordered in conjunction with a positive PLA, but the policy notes a lack of published evidence regarding clinical value and therefore characterizes DermTech Nevome as having insufficient demonstrated clinical utility.

    CAD systems evaluated in the literature have largely been studied in selected, referred populations; reviewers were unable to generalize performance to community or unreferred populations. The evidence is also insufficient to support reliable detection of keratinocyte cancers (BCC, cSCC) by CAD, and the policy emphasizes that data are too limited to recommend specific systems for routine practice.

    Across multiple comparative studies, dermoscopy remains the best pre‑operative diagnostic tool for pigmented lesions and melanoma screening versus newer adjunctive techniques. Some technologies (for example, SIAscopy / spectrophotometric approaches) have shown lower specificity in studies and therefore should not replace dermoscopy for pre‑operative assessment.

    Adhesive patch–based genomic assays (PLA and related platforms) have documented operational limits: they cannot be used on mucous membranes, the palms of the hands, or the soles of the feet. This anatomical restriction applies to current adhesive‑patch collection techniques described in the studies and product information.

    Studies and guidance emphasize that a negative PLA result should not override clinical judgment. If a lesion has additional risk factors or there is persistent clinical suspicion or patient concern, the lesion should undergo surgical biopsy despite a negative PLA; PLA is intended as an adjunct to, not a replacement for, histopathologic diagnosis in such cases.

    The policy reiterates that adhesive‑patch technologies are anatomically limited: they are not suitable for mucous membranes, palms, or soles, which is noted as a principal restriction of current noninvasive patch assays.

    Although multiple studies report high negative predictive values for PLA in intended‑use populations, systematic assessments and health‑technology appraisals have highlighted uncertainty in diagnostic accuracy and the cost‑effectiveness of PLA. The evidence base is described as low quality in some reviews, and cost‑effectiveness analyses have important limitations, which may constrain broader coverage or public funding decisions.

    Reflectance confocal microscopy (RCM) shows promise in some settings for evaluating suspicious lesions, but the evidence is limited and heterogeneous. There is insufficient evidence to support RCM as a standalone diagnostic replacement for biopsy for basal cell carcinoma or cutaneous squamous cell carcinoma in general populations, and primary studies have methodological and applicability concerns.

    RCM has intrinsic limitations that affect diagnostic performance: restricted depth penetration can prevent visualization of deeper lesion features, and terminology and interpretation for non‑melanocytic lesions lack uniform consensus, which may reduce reliability and lead to misclassification in some cases.

    This Clinical Policy Bulletin provides a concise, selective description of plan‑level coverage positions and supporting evidence; it is intended to assist administration of benefits but does not constitute a contract and does not replace plan documents, medical necessity determinations, or provider clinical judgment.

    The policy lists specific codes and technologies (for example, DermTech PLA / patch assays, AURA Raman spectroscopy, computerized TBP systems, and electrical impedance spectroscopy devices) and provides context about their intended uses and coverage stance. Some codes (e.g., CPT 96904) are covered when documented selection criteria are met; other listed codes for experimental or unproven technologies are identified as not covered for the indicated uses. Documentation of indication, device outputs, and clinical rationale is recommended when these technologies are used in practice.

    Comparative reviews conclude that computerized TBP/CAD systems have demonstrated high sensitivity in selected studies but the evidence is heterogeneous and of limited quality. There is insufficient evidence that computerized TBP systems improve health outcomes compared with conventional TBP, and their role in community or unreferred populations remains unproven.

    Overall, many studies are small, heterogeneous, or subject to bias; the policy highlights that the current evidence base is insufficient or low quality for numerous emerging noninvasive diagnostics, limiting confidence in conclusions about diagnostic accuracy, clinical utility, and downstream health outcomes.

    Hand‑held fluorescent molecular imaging systems (for example, the Orlucent device) are described as investigational in the policy because evidence of effectiveness is lacking for evaluating a mole’s transition to atypia; clinical trials are ongoing but current data do not support routine clinical use.

    High‑frequency ultrasound (HFUS) and ultra‑high‑frequency ultrasound have been studied as adjuncts for lesion and sentinel lymph node assessment, but evidence is preliminary and heterogeneous. HFUS may detect larger nodal metastases (macrometastases) but has low sensitivity for micrometastases and cannot replace sentinel lymph node biopsy; available studies are insufficient to support HFUS as a diagnostic replacement.

    Mind.Px (a dermal biomarker patch and NGS‑based transcriptomic classifier) has analytic and early clinical validation data but no published net health‑outcome studies in routine clinical practice. The policy notes a lack of published clinical practice data and concludes that clinical utility and effect on long‑term outcomes remain unestablished.

    Mind.Px lacks published evidence demonstrating net health benefit in clinical practice. Separately, evidence for RCM in diagnosing non‑melanocytic skin cancers (BCC, cSCC) is limited and heterogeneous; routine substitution of these modalities for histopathology is not supported by current data.

    Sequential digital dermoscopy (SDD) and TBP are guideline‑recommended surveillance strategies for high‑risk patients and can detect some slow‑growing melanomas by documenting change over time. However, studies show that in low‑risk populations long‑term SDD may not demonstrably improve early diagnosis compared with periodic hand‑held dermoscopy, and evidence is insufficient to support broad application of long‑term SDD in low‑risk subjects.

    Coding

    Covered CPT Codes (if selection criteria met)CPTCovered
    96904Whole body integumentary photography, for monitoring of high-risk patients with dysplastic nevus syndrome or a history of dysplastic nevi, or patients with a personal or family history of melanoma.
    Codes associated with experimental / not covered technologiesmixedNot Covered
    0089UOncology (melanoma), gene expression profiling by RTqPCR, PRAME and LINC00518, superficial collection using adhesive patch(es).
    0258UAutoimmune (psoriasis), mRNA, next- generation sequencing, gene expression profiling of 50-100 genes, skin-surface collection using adhesive patch, algorithm reported as likelihood of response to psoriasis biologics.
    0635UAutoimmune (atopic dermatitis), mRNA, next generation sequencing (NGS), gene expression profiling of 487 genes, noninvasive skin surface scraping, algorithm reported as likelihood of response to therapy [AdvanceAD-Tx].
    0658TElectrical impedance spectroscopy of 1 or more skin lesions for automated melanoma risk score.
    0700TMolecular fluorescent imaging of suspicious nevus; first lesion.
    0701TMolecular fluorescent imaging of suspicious nevus; each additional lesion.
    1020TRaman spectroscopy of 1 or more skin lesions, with probability score for malignant risk derived by algorithmic analysis of data from each lesion [AURA system (Vita Imaging)].
    96931Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin.
    96932Reflectance confocal microscopy (additional or related codes listed 96931-96936 in policy).
    Other related CPT codesCPT
    17311Mohs micrographic technique and related services (example of other related CPT codes).
    17312Mohs micrographic technique (related series 17311–17315 referenced).
    ICD-10 codes referencedICD-10
    C43.0 - C43.9Malignant melanoma of the skin
    D22.0 - D23.9Melanocytic nevi and other benign neoplasms of the skin
    Z80.8Family history of malignant neoplasm of other organs or systems
    Z85.820Personal history of malignant melanoma of skin
    Z85.828Personal history of other malignant neoplasm of skin
    Z86.018Personal history of other benign neoplasm (dysplastic nevus)
    Z87.2Personal history of diseases of the skin and subcutaneous tissue (atypical and dysplastic nevus)
    C44.01, C44.111 - C44.1192, C44.211 - C44.219, C44.310 - C44.319, C44.41, C44.510 - C44.519, C44.611 - C44.619, C44.711 - C44.719, C44.81, C44.91Basal cell carcinoma and other non-melanoma skin cancer codes (listed as not covered for certain indications)
    L08.89 - L08.9Other local infections of skin and subcutaneous tissue
    L20.0 - L20.9Atopic dermatitis
    1–10 of 12
    1/2
    Codes mentionedmixed
    No codes listed
    Repeat interval for TBP/dermoscopy — typical maximum frequency every 24 months
    Repeat interval for TBP/dermoscopyNot typically more frequently than every 24 months
    Covered CPT code for TBP96904 — whole body integumentary photography when selection criteria are met (history of atypical/dysplastic nevi, melanoma, or non‑melanoma skin cancer)
    Indications for TBP/dermoscopyAtypical nevi; Dysplastic nevi; Melanoma; Non‑melanoma skin cancers
    Documentation requirement when billing 96904Record indication and intended monitoring interval to support that selection criteria are met
    EIS score thresholds — score ≥7 prompts excision in one protocol; 0–6 monitored with SDDI

    Provider Actions and Billing Considerations

    Billing Rule

    CPT 96904: bill only if selection criteria met

    CPT 96904 (whole body integumentary photography) is covered only when the member meets the policy’s selection criteria—examples include high‑risk patients with dysplastic nevus syndrome, a history of dysplastic nevi, or a personal or family history of melanoma. Repeat studies are not typically required more frequently than every 24 months.

    • Use CPT 96904 only for members who meet listed high‑risk indications (atypical nevi, dysplastic nevi, melanoma, or non‑melanoma skin cancers).
    • Document intended monitoring interval; typical maximum frequency ~24 months.
    Prior Authorization

    Consider prior authorization for AdvanceAD‑Tx (limited evidence)

    AdvanceAD‑Tx and similar molecular therapy‑selection tests currently have limited evidence (single prospective validation); prior authorization may be appropriate and payers may request supporting documentation until stronger guideline support exists.

    Definitions

    Total body photography (TBP) and dermoscopy are noninvasive imaging modalities used to document and longitudinally monitor cutaneous lesions to support earlier detection of skin cancer in higher‑risk patients. Dermoscopy improves diagnostic accuracy compared with naked‑eye examination but is operator dependent; histopathology remains the diagnostic gold standard. TBP can aid surveillance of patients with numerous nevi or a history of melanoma and is typically used at intervals not more frequent than 24 months unless clinically indicated.

    inv-87: Total body photography (TBP) — definition and use
    DefinitionTotal body photography (TBP) is digital imaging to record and store baseline and sequential photographs of the skin surface (whole‑body and single‑lesion views) for longitudinal comparison and surveillance
    Primary useUsed to monitor individuals with numerous nevi or elevated melanoma risk (personal/family history, atypical/dysplastic nevi) to detect new or changing lesions
    Clinical benefitSystematic review evidence suggests TBP is associated with detection of melanomas at earlier stages and may reduce unnecessary biopsies by documenting lesion stability

    Background

    TBP and dermoscopy function as noninvasive imaging tools for baseline documentation and longitudinal comparison of skin lesions. When used appropriately in selected high‑risk patients, these techniques facilitate monitoring for change over time and support decisions about biopsy versus clinical surveillance, but they are not substitutes for histologic diagnosis when clinical concern persists.

    Revision History

    1997-12-01effective_date

    Policy became effective.

    2026-08-04last_review

    Policy last reviewed.

    2027-02-11next_reviewLatest

    Next scheduled policy review date.

    Policy Summary
    PayerAetna
    PolicyTotal Body Photography, Dermoscopy and Other Selected Noninvasive Dermatologic Tests
    Policy CodePolicy 0188
    Change TypeNo material clinical or coverage changes
    Effective DateDec 1, 1997
    Last ReviewFeb 11, 2027
    Next Review DateFeb 11, 2027
    Key ActionWhen billing CPT 96904 for whole-body integumentary photography, document that the member meets selection criteria (e.g., personal or family history of melanoma or dysplastic nevi) and the intended monitoring interval.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions and Billing ConsiderationsDefinitionsBackgroundRevision History
    HFUS limitations: High-frequency ultrasound may detect larger sentinel-node metastatic deposits (approx. >=4.5 mm) but has low overall sensitivity for micrometastases and cannot replace sentinel lymph node biopsy; it can be useful for pre-operative assessment or post-operative monitoring.>=4.5 mm

    Utility is limited by low sensitivity for typical SLN metastatic deposit sizes.

    MelaFind / CAD device observations:
    Some image-analysis devices (eg, MelaFind) showed very high sensitivity in trial data (e.g., reported 98.4%) but low specificity, raising questions about net clinical utility despite sensitivity advantages.
    sensitivity reported as high as 98.4% in device studies

    High sensitivity accompanied by low specificity may lead to many false positives in practice.

    EIS score prompting excision in protocolEIS score ≥7 prompted immediate excision in a protocol combining EIS with short‑term SDDI
    EIS scores monitored with SDDIEIS scores 0–6 were monitored with short‑term sequential digital dermoscopy imaging (SDDI)
    Protocol effect on SDDI useUsing a protocol with EIS thresholds reduced need for SDDI by 46.9% in the reported study
    EIS malignancy score threshold — score <4 suggests no malignancy (study context)
    EIS malignancy score cutoff suggesting no malignancyEIS score <4 suggested no malignancy in a study of lesions examined with EIS and RCM
    Caution with low EIS scoresLesions with EIS <4 that show changes on dermoscopic follow‑up may still require short‑term monitoring or excision based on clinical/dermoscopic criteria
    Study limitationsEIS results in very early lesions should be carefully considered due to risk of false negatives
    Ultrasound detectable metastasis size — approx ≥ 4.5 mm diameter threshold for SLN detection
    Approximate ultrasound detection threshold for SLN metastasesTargeted high‑resolution ultrasound can detect sentinel lymph node metastatic deposits down to approximately 4.5 mm in diameter
    Clinical limitationMost SLN metastatic deposits at initial staging are smaller than this, limiting US sensitivity for staging
    Role of HFUSUseful for pre‑operative assessment and post‑operative monitoring but not a substitute for sentinel lymph node biopsy
    HFUS frequency threshold — >= 20 MHz
    HFUS frequency threshold>= 20 MHz — high‑frequency/high‑resolution ultrasound used for skin lesions and sentinel lymph node assessment
    Intended useApplied to skin lesions or SLNs to assess lesion characteristics or metastatic deposits
    Sensitivity limitationHFUS has low sensitivity for micrometastases and cannot replace SLN biopsy
    US-detectable metastatic deposit size — approx ≥ 4.5 mm diameter (supporting citations)
    Ultrasound‑detectable metastatic deposit size (supporting)Sonographic and histologic data indicated true‑positive US‑detected SLN metastases were generally larger (undetected deposits had diameters <4.5 mm), supporting ~4.5 mm as an approximate detection threshold
    Reported sensitivityOverall sensitivity of targeted high‑resolution US for positive SLNs was 24.3% (95% CI 19.5%–28.7%)
    SpecificityReported specificity for targeted US was 96.8% (95% CI 95.9%–97.7%)
    • Evidence limited to a single prospective validation study with modest sample size.
    • Expect payers to request documentation of indication and rationale if submitted for coverage consideration.
    Note

    No PA rules stated in these excerpts

    No explicit prior authorization requirements or codes are specified in the cited policy excerpts for the technologies described in these sections.

    • Policy text in these chunks does not list PA rules or specific CPT/HCPCS codes requiring prior authorization.
    Note

    No explicit prior authorization in this section

    The provided policy excerpts do not state explicit prior‑authorization rules for the devices and tests discussed in these chunks.

    • Review other policy sections or payer plan provisions for any local PA requirements.
    Prior Authorization

    Assay/device descriptions relevant to PA considerations

    The document describes commercially available non‑invasive assays and devices (e.g., DermTech PLA, MelaFind, MoleSafe, multi‑photon devices) which provide context for potential PA considerations, but does not list specific PA codes here.

    • These descriptions can inform PA requests that seek device/test details and rationale for clinical use.
    Note

    No PA or code restrictions stated here

    These chunks do not include explicit prior authorization requirements or billed‑code restrictions for the technologies discussed.

    • Providers should verify plan‑specific PA rules as they are not specified in these excerpts.
    Note

    PA not addressed; PLA alters management in studies

    Clinical utility studies report PLA results alter management (PLA(+) → biopsy in the vast majority; PLA(−) → surveillance in ~99%), but prior authorization is not addressed in this excerpt.

    • Document PLA result and management to support clinical decisions when used.
    Note

    No PA specified; document appropriate use

    No explicit prior authorization requirements are specified in these chunks; evidence summaries emphasize appropriate patient selection and documentation when using non‑invasive tests.

    • Provide indication and supporting documentation if payer requests prior authorization.
    Prior Authorization

    Limited evidence—prior authorization may be required

    Given limited and variable evidence for some tests, prior authorization is likely to be required and payers may request supporting documentation including indication, prior treatments, and rationale for use (e.g., Mind.Px or RCM).

    • Prepare to supply clinical indication, prior therapy history, and justification of how the test will change management.
    Prior Authorization

    PA consideration for SDD/TBP—document guideline‑recommended high‑risk use

    SDD and TBP are guideline‑recommended for high‑risk subjects; when used for monitoring these patients, clinicians should be prepared to document guideline‑based indication and follow‑up plans if prior authorization or coverage justification is requested.

    • Use TBP/SDD primarily for high‑risk patients; justify use in low‑risk patients if requested.
    Note

    No PA specified in policy history excerpt

    This excerpt (policy history/review dates) does not specify prior authorization requirements for CPT/HCPCS codes in this section.

    • Check plan‑level PA policies; the Clinical Policy Bulletin itself does not guarantee PA procedures.
    Note

    No PA requirements in additional information

    No prior authorization requirements are stated in the additional information sections cited.

    • Providers remain responsible for verifying plan‑specific PA requirements.
    Step Therapy

    No step therapy requirements specified

    The policy does not specify any step therapy requirements for the devices and tests discussed in these chunks.

    • No stepwise testing or treatment algorithms are defined in this portion of the policy.
    Step Therapy

    Step therapy: not applicable in these excerpts

    Explicit step therapy rules are not provided in this document segment and therefore are not applicable here.

    • Mind.Px and AdvanceAD‑Tx are discussed as precision tests but no step therapy sequencing is mandated.
    Step Therapy

    No step therapy algorithms provided

    No step therapy algorithms are described in these policy excerpts.

    • Providers should follow clinical guidelines and plan formularies for therapy sequencing.
    Step Therapy

    No step therapy; EIS may complement dermoscopy

    No formal step therapy algorithms are described; evidence suggests EIS may complement dermoscopy for less‑experienced providers but does not define mandatory steps.

    • Consider using EIS as an adjunct to dermoscopy, particularly if not routinely trained in dermoscopy, but document clinical exam findings.
    Step Therapy

    PLA results commonly used as a pre‑biopsy decision step

    Studies describe PLA‑guided management where PLA(+) lesions are typically biopsied and PLA(−) lesions are monitored—functioning as a decision step before surgical biopsy in practice, though the policy does not formalize a step therapy requirement.

    • Record PLA result and the subsequent management decision (biopsy vs surveillance) in the medical record.
    Step Therapy

    No step therapy rules stated

    No step therapy requirements are specified in these cited chunks.

    • Continue to follow standard clinical pathways when PLA or other adjunctive tests are inconclusive.
    Note
    Note
    Step Therapy

    Mind.Px may influence biologic selection (affects stepwise therapy)

    Mind.Px is intended to inform biologic class selection for psoriasis to reduce empirical trial‑and‑error prescribing and may affect stepwise biologic selection; clinical utility studies used baseline and follow‑up PASI scores to assess outcomes.

    • If used to guide biologic selection, document baseline PASI and follow‑up PASI (weeks 4 and 12) and the rationale for choosing the biologic informed by Mind.Px.
    Note

    No provider actions specified in these excerpts

    No additional provider actions are specified in the cited excerpts.

    • Refer to full policy or plan provisions for any further requirements.
    Note
    Step Therapy

    No step therapy requirements mentioned

    These chunks do not mention any step therapy requirements for the tests or devices discussed.

    • Providers should follow plan‑specific utilization management rules where applicable.
    Documentation Required

    Document indication and monitoring interval when billing 96904

    When billing CPT 96904 for whole‑body integumentary photography, document that the member meets the policy selection criteria (e.g., atypical or dysplastic nevi, personal/family history of melanoma) and record the intended monitoring interval (repeat studies generally not more frequent than every 24 months).

    • Include clinical indication and planned follow‑up interval in the chart when billing 96904.
    • Ensure documentation shows high‑risk status per policy indications.
    Documentation Required

    Include device outputs and demographic inputs in documentation

    For FDA‑validated devices and algorithms (e.g., AURA), include device‑generated diagnostic outputs and any patient demographic inputs used by the algorithm when submitting documentation for clinical decision‑making or coverage review.

    • Document device output, algorithm version, and demographic variables used in analysis if relied upon for diagnostic decisions.
    Note

    No extra documentation rules in these excerpts (histopathology used in studies)

    These chunks do not specify additional documentation requirements beyond study descriptions, which note use of histopathology confirmation and EIS scoring thresholds in protocols.

    • When applicable, retain histopathology reports that correlate with non‑invasive test results.
    Documentation Required

    Document in‑clinic exam and rationale when adjunctive tests lead to surveillance

    Document the in‑clinic, in‑vivo examination and the clinical rationale when adjunctive test results (for example an EIS score interpreted as low) lead to monitoring instead of excision; note any limitations of ancillary tests and plan for short‑term reassessment if indicated.

    • Record lesion appearance on dermoscopy, EIS score, and reason for choosing surveillance versus biopsy.
    • Plan and document follow‑up interval and reassessment criteria.
    Documentation Required

    Record PLA result, genes tested (LINC00518, PRAME), and management decision

    When PLA is used, document the PLA test result including which genes were assessed (LINC00518, PRAME), the clinical decision taken (biopsy versus surveillance), and the planned follow‑up interval.

    • Include PLA gene detection status (LINC, PRAME, or both) and how result informed management.
    • Retain corresponding histopathology if biopsy performed or follow‑up notes if surveilled.
    Documentation Required

    Keep biopsy pathology and documented follow‑up to support test performance

    Studies establishing test performance relied on biopsy pathology reports and documented clinical follow‑up; providers should retain biopsy pathology and evidence of adequate follow‑up to validate outcomes when using non‑invasive tests.

    • Maintain biopsy pathology reports or documented clinical monitoring for the follow‑up period used in validation studies (e.g., 3–12 months or longer as applicable).
    Documentation Required

    Record PLA result and the subsequent management decision

    Clinical management in studies commonly followed PLA results (PLA(+) → biopsy; PLA(−) → surveillance); providers should record the PLA result and the resulting management decision in the medical record.

    • Document concordance between PLA result and clinical action, and rationale if management deviates from typical PLA‑guided pathways.
    Documentation Required

    Retain biopsy reports and follow‑up documentation to validate results

    Supporting documentation used in studies and registries included biopsy pathology reports and documented clinical follow‑up; providers should retain these sources when using PLA or similar tests to support clinical outcomes.

    • Ensure follow‑up durations and outcomes are documented when relying on non‑invasive test results to avoid gaps that could undermine a negative test’s assumed NPV.
    Documentation Required

    Document baseline and follow‑up PASI when using Mind.Px

    Mind.Px utility in trials was supported by documentation of baseline and follow‑up PASI scores (weeks 4 and 12); if using Mind.Px to guide biologic selection, document baseline PASI and subsequent PASI assessments to support clinical benefit.

    • Record baseline PASI and follow‑up PASI at the time points used in studies (week 4 and week 12) when presenting evidence of clinical response tied to Mind.Px‑guided therapy.
    Documentation Required

    Document image acquisition details and reference standard for teledermatology

    For teledermatology assessments, document image acquisition details (who acquired images, device type, settings) and the reference standard used (histology, clinical follow‑up, or face‑to‑face specialist decision) to support diagnostic claims.

    • Include image source, resolution, dermoscopic versus clinical photo, and comparator (biopsy or follow‑up) in the medical record.
    Documentation Required

    Use Clinical Policy Bulletins and document per plan provisions

    Providers must use Clinical Policy Bulletins to assist in administering plan benefits and ensure documentation aligns with plan provisions; Clinical Policy Bulletins are not guarantees of coverage.

    • Confirm coverage and PA rules with the member’s plan; document justification per plan requirements.
    Note
    Denial Risk

    Risk of denial when billing experimental/computerized TBP systems

    Services using computerized TBP systems (e.g., MelaFind, MoleMapCD, MoleMate, MoleSafe) and other listed experimental technologies are identified in the policy as not covered for the evaluated indications; billing these services for those indications risks denial.

    • Do not bill covered TBP CPT 96904 for computerized TBP systems that the policy lists as experimental for the indicated uses.
    • If such devices are used, be prepared for likely claim denial for the indicated (non‑covered) uses.
    Denial Risk

    CAD tools (e.g., MoleMate) can increase inappropriate referrals—risk of denial

    Randomized trial data showed MoleMate did not improve appropriateness of referrals and increased referrals without improving referral appropriateness; reliance on such CAD tools in lieu of guideline‑based assessment may increase risk of inappropriate referrals and potential denials.

    • When using CAD tools, also document clinician exam and guideline‑based rationale for referral to reduce risk of inappropriate referral denials.
    Note

    No explicit billing/authorization rules in these excerpts

    These chunks do not specify coverage authorization or billing requirements for the technologies discussed.

    • Verify plan‑specific billing rules; absence of statements here does not imply coverage.
    Documentation Required

    Avoid decisions based solely on adjunctive device outputs (EIS) — document combined assessment

    Diagnostic adjuncts like EIS can produce false negatives or false positives; avoid making management decisions based solely on device outputs without in‑vivo clinical assessment and document the combined clinical and device findings to support management.

    • Record both dermoscopic/in‑clinic exam findings and the EIS score when EIS influences biopsy versus surveillance decisions.
    • If management deviates from device recommendation, document the clinical rationale.
    Documentation Required

    If deviating from PLA guidance, document additional clinical rationale

    If management departs from PLA guidance (for example failing to biopsy a PLA(+) lesion or biopsying a PLA(−) lesion without documented additional clinical concern), document the additional clinical rationale and supporting evidence to justify the decision.

    • Provide clear documentation of additional risk factors or findings that prompted deviation from PLA‑guided pathways.
    Note

    Biopsy despite negative PLA when clinical concern persists—document reasons

    If additional risk factors or persistent clinical suspicion exist despite a negative PLA, perform and document a surgical biopsy—clinical judgment supersedes test results when concern remains.

    • Document the specific risk factors or suspicious features that prompted biopsy despite a negative PLA.
    Denial Risk

    Risk from inadequate follow‑up of PLA(−) lesions—ensure documented reassessment

    Inadequate follow‑up of PLA(−) lesions can undermine the assumed negative predictive value; ensure and document appropriate reassessment and surveillance intervals to support a non‑biopsy management plan.

    • Document planned surveillance intervals and any repeat testing or re‑examination timelines.
    Denial Risk

    Overuse risk—document clear clinical indication to avoid denials

    Overuse of non‑invasive tests for reassurance in inappropriate patients may lead to inappropriate testing and potential denials; document clinical indication and why testing is necessary rather than for patient reassurance alone.

    • Include specific clinical indications and risk factors in the chart to justify use of non‑invasive diagnostic tests.
    Denial Risk

    Evidence limitations may trigger non‑coverage—document rationale when using RCM

    Evidence limitations (high/unclear risk of bias and applicability concerns) for some technologies (eg, RCM) may lead to non‑coverage or denial if used in place of histopathology; document rationale and supporting evidence if relying on these modalities.

    • When using RCM for diagnostic decisions, retain supporting evidence and document why biopsy was deferred.
    Denial Risk

    Teledermatology: ensure appropriate selection and documentation to avoid denials

    Teledermatology studies often had high/unclear bias and limited applicability; ensure appropriate patient selection and thorough documentation when relying on teledermatology to support triage or diagnosis to reduce denial risk.

    • Document image acquisition, who reviewed the images, and the reference standard used (biopsy or follow‑up).
    Denial Risk

    Coverage and denial risk note—CPBs do not guarantee coverage

    Clinical Policy Bulletins provide a partial description of benefits and do not guarantee coverage; providers are independent and responsible for treatment decisions—lack of documentation or failure to meet plan criteria may result in denials.

    • Confirm member coverage and document clinical justification per plan requirements before billing.
    Note

    External links are informational only—do not affect coverage rules

    Links to external (non‑Aetna) resources are provided for convenience only; Aetna is not responsible for external content or privacy practices—these links do not change coverage or documentation requirements.

    • Do not rely on external links as substitute for payer documentation or plan provisions.
    inv-88: Dermoscopy (dermatoscopy, epiluminescence microscopy) — definition
    DefinitionDermoscopy (dermatoscopy/epiluminescence microscopy) is a noninvasive diagnostic technique using magnification and specialized lighting to visualize subsurface structures of the epidermis and superficial dermis
    RoleServes as an adjunct to clinical examination to improve diagnostic accuracy for melanoma versus naked‑eye inspection; histopathology remains the gold standard
    SynonymsAlso referred to as DELM, ELM, skin videomicroscopy, melanomography, in‑vivo cutaneous surface microscopy, dermatoscopy
    inv-89: High-frequency ultrasound (HFUS) / UHFUS — definition and investigational uses
    DefinitionHigh‑frequency ultrasound (HFUS / UHFUS) is targeted ultrasound using frequencies ≥20 MHz to image skin lesions and sentinel lymph nodes for assessment of lesion characteristics, margins, and vascularization
    Investigational usesInvestigated for pre‑operative study of basal cell carcinoma margins and for sentinel lymph node assessment, but not yet routine for diagnosis
    Performance limitsDetects macrometastases (~≥4.5 mm) but has low sensitivity for micrometastases; cannot substitute for sentinel lymph node biopsy
    inv-90: Raman spectroscopy (AURA) — definition
    DefinitionRaman spectroscopy (AURA) is a noninvasive optical technique that generates a molecular 'fingerprint' of a skin lesion in real time to aid differentiation of malignant and benign lesions
    Device exampleThe AURA system (Vita Imaging) provides real‑time results (molecular fingerprint) and has reported ROC values in clinical studies, though specificity varies with sensitivity settings
    Clinical noteReported sensitivities between 95%–99% corresponded to specificities ranging approximately 15%–54% in early in‑vivo studies
    inv-91: Molecular patch tests (DermTech Nevome, PLA) — definition and markers analyzed
    DefinitionMolecular patch tests (eg, DermTech Nevome, Pigmented Lesion Assay [PLA]) are noninvasive adhesive patch‑based assays that analyze gene expression and/or DNA mutations from stratum corneum samples to assess melanoma risk
    Markers analyzedPLA/2‑GEP measures expression of LINC00518 and PRAME (and historically CMIP); Nevome analyzes mutations in BRAF, NRAS, and TERT promoter genes
    Clinical contextThese assays are intended to help rule out melanoma and guide biopsy decisions; PLA has reported high NPV (>99%) in intended‑use cohorts
    inv-92: Derm-CAD — definition and pooled performance metrics
    DefinitionDerm‑CAD refers to computer‑aided diagnosis systems based on digital dermoscopy images that analyze lesion features via algorithms to assist melanoma detection
    Pooled performancePooled sensitivity for Derm‑CAD ~90.1% and pooled specificity ~74.3% for melanoma detection in selected study populations
    LimitationsStudies heterogeneous and at unclear/high risk of bias; generalizability to routine practice is limited
    inv-93: MSI-CAD / Spectro-CAD — definition and performance note
    DefinitionMSI‑CAD / Spectro‑CAD denotes spectroscopy or multispectral imaging–based CAD systems that analyze spectral image data to identify malignant lesions
    Performance noteHigh pooled sensitivity (eg, MSI‑CAD ~92.9%) but lower pooled specificity (~43.6%), indicating many false positives in selected studies
    Study limitationsConsiderable variation in hardware/software and high heterogeneity across studies limit applicability
    inv-94: Electrical impedance spectroscopy (EIS) — definition and score range
    DefinitionElectrical impedance spectroscopy (EIS) is a handheld, noninvasive device that measures tissue electrical impedance and produces a numeric score (0–10) to aid differentiation of benign and malignant lesions
    Score rangeEIS outputs a score from 0 to 10 used to stratify malignancy risk; various study‑specific thresholds (eg, ≥4, ≥7) have been evaluated
    Clinical roleEIS may increase sensitivity of biopsy decisions, especially among less‑experienced clinicians, but has low specificity in some datasets and should be integrated with dermoscopy and clinical exam
    inv-95: Electrical Impedance Spectroscopy (EIS) — alternate entry / device description
    Device descriptionEIS is a noninvasive device that measures electrical impedance of skin lesions to aid melanoma detection; pivotal studies reported very high sensitivity but low overall specificity
    Clinical impactWhen combined with clinician assessment, EIS has been shown in surveys and pilot studies to change biopsy decisions and increase sensitivity, particularly for less‑experienced users
    Study caveatMany studies used image‑based or selected lesion cohorts, limiting in‑vivo and real‑world applicability
    inv-96: Spectrophotometric intra-cutaneous analysis (SIAscopy / SPT) — definition and performance
    DefinitionSpectrophotometric intra‑cutaneous analysis (SIAscopy / SPT) is a noninvasive method analyzing dermal pigment, vascularity, and collagen integrity to evaluate pigmented lesions
    Performance noteIn some studies SIAscopy showed high sensitivity (eg, 100%) but lower specificity (eg, 59%) compared with dermoscopy, limiting its standalone diagnostic utility
    Clinical roleProduces dermoscopic images for training/archiving but dermoscopy remains superior for pre‑operative diagnosis
    inv-97: High-frequency ultrasonography — definition and intended uses
    DefinitionHigh‑frequency ultrasonography is targeted ultrasound using frequencies ≥20 MHz to image skin lesions and regional lymph nodes for characterization of lesion depth, margins, and nodal metastases
    Intended usesInvestigated for pre‑operative assessment of basal cell carcinoma margins and for detection of sentinel lymph node macrometastases; may assist surgical planning and monitoring
    LimitationLow sensitivity for micrometastases (overall SLN detection sensitivity ~24.3%) prevents replacement of SLN biopsy
    inv-98: Hand-held fluorescent molecular imaging (Orlucent) — definition
    DefinitionHand‑held fluorescent molecular imaging (Orlucent) is a topical fluorescent biotag imaging system intended to detect early tissue changes during a mole’s transition to atypia at point‑of‑care
    Evidence statusClinical effectiveness is currently lacking and the technology is considered investigational in this policy context
    Intended impactAims to provide molecular information to support evaluation of suspicious moles, but trials are ongoing to establish clinical thresholds and outcomes
    inv-99: Pigmented Lesion Assay (PLA) — definition and gene targets
    DefinitionPigmented Lesion Assay (PLA) is a noninvasive adhesive patch‑based gene expression test that measures expression of melanoma‑associated genes to help distinguish melanoma from non‑melanoma lesions
    Gene targetsVersions of the assay analyze genes including LINC00518 and PRAME (2‑GEP) and in some reports CMIP; mutation analysis (eg, BRAF, NRAS, TERT) may be used adjunctively
    Clinical utilityPLA has demonstrated high negative predictive value (>99% in multiple cohorts) and has been used to guide biopsy versus surveillance decisions in practice
    inv-100: High-frequency/high-resolution ultrasonography (HFUS) — definition
    DefinitionHigh‑frequency / high‑resolution ultrasonography (HFUS) uses ultrasound frequencies ≥20 MHz to evaluate skin lesions and sentinel lymph nodes for lesion depth, margins, and metastatic deposits
    ApplicationsApplied for pre‑operative assessment of BCC margins and for SLN assessment, with value for macrometastases detection and post‑operative monitoring
    LimitationsLimited sensitivity for micro‑metastases; cannot substitute for sentinel lymph node biopsy
    inv-101: MelaFind / MoleSafe — definition
    DefinitionMelaFind / MoleSafe describes computer‑vision and image‑analysis systems that objectively analyze lesion images to assist clinicians in evaluating pigmented lesions
    Performance exampleMelaFind reported very high sensitivity (~98.4%) but low specificity (~9.9% in some analyses), raising clinical utility concerns despite sensitivity
    Policy stanceComputerized TBP systems like MelaFind, MoleMapCD, MoleMate are listed as experimental/investigational because improved health outcomes versus conventional TBP are not established
    inv-102: Pigmented Lesion Assay (PLA) / 2-GEP — definition (PRAME & LINC00518)
    Definition2‑GEP is a two‑gene expression test (Pigmented Lesion Assay) assessing expression of LINC00518 and PRAME to classify lesions as genomically atypical (positive) or not detected (negative)
    Clinical useIntended as a rule‑out/rule‑in adjunct to visual assessment to guide biopsy decisions for suspicious pigmented lesions
    ValidationValidation studies reported sensitivities ~91% and specificities ~69% in initial cohorts; real‑world registries report high NPV (>99%)
    inv-103: Negative predictive value (NPV) — definition and reported performance for PLA
    Definition (NPV)Negative predictive value (NPV) is the probability that lesions testing negative truly do not have melanoma
    Reported performance for PLAMultiple real‑world and validation cohorts report PLA NPV >99% (eg, 99.2% in a 1,233 lesion cohort; 99.7% in a 19,653 lesion registry analysis)
    Clinical implicationHigh NPV supports PLA use as a rule‑out adjunct to reduce unnecessary biopsies in intended‑use populations when combined with appropriate follow‑up
    inv-104: PLA — short form definition
    Short formPLA: noninvasive adhesive patch gene expression test used to aid differentiation of melanoma vs non‑melanoma lesions
    Primary genes2‑GEP PLA analyzes PRAME and LINC00518; some versions included CMIP historically
    Clinical use caseUsed to guide biopsy decisions and surveillance intervals for suspicious pigmented lesions in intended populations
    inv-105: 2-GEP — two-gene expression test definition
    Definition2‑GEP is a genomic assay measuring two gene targets (LINC00518 and PRAME) from noninvasive adhesive patch samples to classify lesions as genomically atypical or not detected
    PurposeProvides adjunctive molecular information to inform biopsy versus surveillance decisions in clinically suspicious pigmented lesions
    PerformanceValidation studies reported sensitivity ~91% and specificity ~69% in initial cohorts
    inv-106: PLA / 2-GEP / ABPLA — definition and gene targets summary
    Definition summaryPLA / 2‑GEP / adhesive patch genomic assays sample stratum corneum to assess expression of melanoma‑associated genes (eg, LINC00518, PRAME) and may include mutation analysis (BRAF, NRAS, TERT) as adjunct
    Gene targetsLINC00518 and PRAME are primary gene expression targets; mutation panels may include BRAF, NRAS, and TERT promoter analysis
    Clinical roleUsed as an adjunct to visual assessment to reduce unnecessary biopsies and assist surveillance decisions in intended‑use populations
    inv-107: Mind.Px dermal biomarker patch (DBP) — definition and NGS biomarker count
    DefinitionMind.Px dermal biomarker patch (DBP) is a minimally invasive patch that extracts mRNA from epidermis and dermis for next‑generation sequencing of >7,000 biomarkers
    Analytic approachNGS‑based transcriptomic data are processed with machine‑learning algorithms to generate reports predicting likely response to biologic therapies in psoriasis
    Evidence statusAnalytic and initial clinical validation (STAMP) and a randomized MATCH utility study exist, but no published net health outcome studies in routine clinical practice yet
    inv-108: Dermal biomarker patch (DBP) — alternate definition entry
    Alternate definitionDermal biomarker patch (DBP) is a minimally invasive patch that extracts mRNA for NGS‑based transcriptomic analysis of epidermal and dermal biomarkers
    Intended useApplied to inform biologic selection for psoriasis by predicting likely therapeutic response based on transcriptomic signatures
    Evidence gapNo published clinical practice net health benefit outcome studies are available to support routine coverage
    inv-109: Reflectance confocal microscopy (RCM) — definition
    DefinitionReflectance confocal microscopy (RCM) is a noninvasive laser‑scanning imaging technique that produces high‑resolution images of skin morphology at multiple depths approximating histologic resolution
    Use caseUsed to evaluate cellular‑level features of skin lesions and as an adjunct to dermoscopy for equivocal lesions; may improve diagnostic accuracy in selected settings
    LimitationsTerminology and interpretation for non‑melanocytic lesions are heterogeneous; depth penetration limits and study bias restrict generalizability
    inv-110: Reflectance Confocal Microscopy (RCM) — alternate definition
    Alternate definitionRCM (reflectance confocal microscopy) is an in‑vivo optical imaging method generating cellular‑level images to aid diagnosis of pigmented and non‑pigmented lesions
    Performance noteSystematic reviews suggest RCM may have higher sensitivity/specificity than dermoscopy for equivocal lesions, but many studies have high/unclear bias
    Practice implicationRCM should not replace histopathology as sole diagnostic standard; interpretive expertise required
    inv-111: Sequential Digital Dermoscopy (SDD) — definition
    DefinitionSequential Digital Dermoscopy (SDD) is longitudinal dermoscopic imaging of lesions to detect change over time, useful for identifying slow‑growing melanomas that lack suspicious baseline features
    Combined useOften used together with TBP for surveillance of high‑risk patients per guideline recommendations
    Clinical noteSDD can enable detection of earlier‑stage melanomas compared with single time‑point hand‑held dermoscopy in some cohorts
    inv-112: Total Body Photography (TBP) — definition
    DefinitionTotal Body Photography (TBP) is wide‑field photographic documentation of the skin surface used alongside SDD to monitor high‑risk patients for new or changing lesions
    Alternate nameAlso referred to as mole mapping or video‑dermoscopy when video imaging is used
    Evidence summarySystematic review evidence (14 studies, n≈12,082) indicates TBP associated with earlier stage melanoma detection and potential biopsy reduction
    inv-113: Teledermatology / Teledermoscopy — definition
    DefinitionTeledermatology / teledermoscopy is remote evaluation of photographic and/or dermoscopic images transmitted electronically to support diagnosis, triage, or specialist consultation
    Performance noteCochrane review summarized teledermatology diagnostic accuracy with high sensitivity (~94.9%) and specificity (~84.3%) for photographic image identification of malignant lesions in select studies
    DocumentationImage acquisition details and reference standard (histology or follow‑up) should be documented for teledermatology assessments
    inv-114: Noninvasive dermatologic tests — umbrella definition
    DefinitionNoninvasive dermatologic tests encompass techniques and devices such as TBP, dermoscopy, reflectance confocal microscopy (RCM), electrical impedance spectroscopy (EIS), adhesive patch genomic assays (PLA), Raman spectroscopy (AURA), and high‑frequency ultrasound (HFUS)
    PurposeThese methods are used to evaluate pigmented and non‑pigmented skin lesions without surgical biopsy to aid detection, surveillance, and pre‑operative planning
    LimitationsMany emerging technologies show promising sensitivity but variable specificity and limited real‑world outcome data; clinical integration requires documentation and follow‑up